Atezolizumab companion diagnostic - Foundation Medicine

Drug Profile

Atezolizumab companion diagnostic - Foundation Medicine

Alternative Names: Atezolizumab bTMB assay

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Foundation Medicine
  • Developer Foundation Medicine; Roche
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 08 Sep 2017 Clinical trials in Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
  • 08 Sep 2017 Foundation Medicine and Roche plan a II/III trial for Non-small cell lung cancer (Diagnosis) in USA, Australia, Belgium, Brazil, Canada, France, Hong Kong, Italy, South Korea, Mexico, Poland, Spain and Thailand in September 2017 (NCT03178552)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top